SCHEMBL3309520

SCHEMBL3309520

O=C(O)C(O)=CC(=O)c1ccncc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.52
HTT P42858 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HPGD P15428 4/20 0.44
MAPT P10636 4/20 0.44
GAA P10253 4/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 2/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
GPR52 Q9Y2T5 1/20 0.44
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 2/20 0.43
ALOX15 P16050 1/20 0.43
CYP1A2 P05177 4/20 0.42
CYP2D6 P10635 4/20 0.42
CYP1A1 P04798 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3309513 1.00 NAPRT (0.52) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL3309518 1.00 NAPRT (0.52) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL3305722 0.80 NFE2L2 (0.64) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL3305728 0.80 NFE2L2 (0.64) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL3305717 0.80 NFE2L2 (0.64) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL2239088 0.80 POLB (0.46) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL5493098 0.80 POLB (0.46) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL2239090 0.80 POLB (0.46) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL2594019 0.79 NAPRT (0.52) NAPRTHTTMEN1KMT2AHPGD
SCHEMBL2594020 0.79 NAPRT (0.52) NAPRTHTTMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-06-19 US claimed
US-9737522-B2 NMDA receptor modulators and uses related thereto EMORY UNIVERSITY (US) 2017-08-22 US disclosed
US-20150196540-A1 NMDA RECEPTOR MODULATORS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2015-07-16 US disclosed
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-06-19 US disclosed
US-8664255-B2 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-03-04 US disclosed
WO-2014025942-A1 NMDA RECEPTOR MODULATORS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2014-02-13 WO disclosed
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof TEXAS A&M UNIVERSITY SYSTEM, THE 2010-05-06 US disclosed
WO-2010047774-A2 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS MALATE SYNTHASE, METHODS OF MARKING AND USES THEREOF THE TEXAS A & M UNIVERSITY SYSTEM (US) 2010-04-29 WO disclosed
US-20070225335-A1 Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor NOVARTIS AG (CH) 2007-09-27 US disclosed
EP-1799206-A2 PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR Novartis AG (CH) 2007-06-27 EP disclosed
WO-2006015860-A2 PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR NOVARTIS AG (CH) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof ME3, ME1, MDH1 NAPRT 394/4885HTT 4341/4885MEN1 1930/4885
US-20150196540-A1 NMDA RECEPTOR MODULATORS AND USES RELATED THERETO GRIN2C, GRIN2A, GRIN3A NAPRT 565/4885HTT 1476/4885MEN1 3110/4885
US-20070225335-A1 Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor ADORA3, ADORA2B, ADORA1 NAPRT 116/4885HTT 3868/4885MEN1 4248/4885
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof ME3, ME1, MDH1 NAPRT 394/4885HTT 4341/4885MEN1 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.